Mclean Hospital
Technology in Psychiatry

McLean Institute for Technology in Psychiatry

The McLean Institute for Technology in Psychiatry (ITP) was founded in 2016 to advance psychiatric research and practice through innovations in digital health technology and informatics.

Learn more about the annual Technology in Psychiatry Summit

To accomplish these goals, we work with global leaders in academia, industry, and healthcare to:

  • Innovate new technology-based methods for diagnosing, monitoring, and treating psychiatric disorders.
  • Support technology-based solutions in research and clinical care.
  • Optimize new and existing technology to meet the needs of clinicians, patients, and the scientific community.

As a freestanding psychiatric hospital and the largest psychiatric affiliate of Harvard Medical School, McLean Hospital provides a unique environment for optimizing treatments and providing support for a wide range of patient-centered research initiatives. ITP brings together the leading minds in technology, science, and clinical care with a shared vision of using technology to improve mental health.

ITP Summit
Watch videos from the 2017
Technology in Psychiatry Summit

Together with partners in academia and industry, ITP develops new technologies for understanding and treating psychiatric illness such as apps, wearables, web-based games, surveys, and video-based platforms. It is the ITP’s mission to incorporate these technologies into research and clinical care to address the most pressing problems in mental health.

In addition to providing leadership in technology development and mental health, ITP offers comprehensive support for navigating the challenges of responsible and ethical discovery. We help organizations and investigators:

  • Conduct clinical trials and clinical research studies that integrate digital phenotypes and/or technology-based patient engagement strategies.
  • Identify the best software and hardware tools for collecting behavioral and physiological data.
  • Define best practices for digital phenotype collection across clinical, laboratory, and external settings (i.e., “in the wild”).
  • Develop streamlined IRB and clinical trials agreements with standardized language for digital protocols to enable more efficient delivery of information and services to cooperating agents/entities and regulatory bodies.
  • Validate new digital health technologies to diagnose and treat mental disorders, as well as monitor variations in psychological and brain functioning that are associated with health and disease.
  • Educate individuals and organizations interested in technology-based mental health interventions and deep phenotyping.

If you are interested in learning more about the McLean Institute for Technology in Psychiatry, please contact us.